JP7095925B1 - Oral composition for stress reduction - Google Patents

Abstract

[Problem] To provide a composition effectively utilizing γ-aminobutyric acid, which is a stress-relieving component. [Solution] An oral composition for stress reduction comprising (A) γ-aminobutyric acid as an active ingredient for stress reduction, further comprising (B) chamomile, and (C) theanine, ceramide, elastin, hyaluronic acid and collagen. or (A) γ-aminobutyric acid, (B) chamomile, and (C) two or more selected from theanine, ceramide, elastin, hyaluronic acid and collagen. An oral composition for stress relief. [Selection figure] None

Description

Application of Article 30, Paragraph 2 of the Patent Act Date of submission of the publication to the Consumer Affairs Agency by Toyo Shinyaku Co., Ltd .: April 21, 2021, Date of publication of publication information by the Consumer Affairs Agency: June 4, 2021 Date, Issue name: Notification documents for foods with functional claims of "Maintenite" by Toyo Shinyaku Co., Ltd., Publication address: https: // www. fld. caa. go. jp / caaks / cssc02 /? recordSeq = 42106090090200

The present invention relates to an oral composition comprising γ-aminobutyric acid and chamomile.

Modern society is a stressful society, and when stress accumulates, it causes weakened immunity, obesity, and hair loss. It is also said that stress can be one of the causes of atopic dermatitis, asthma, chronic hepatitis, angina, and diabetes.

As the stress-reducing component, for example, calculus bovis (Patent Document 1), calculus bovis, ginseng, oyster, licorice, and ginger (Patent Document 2) are known. However, in a stressed society, it is strongly desired to develop a combination that improves the effect of stress reduction, not just a component that reduces stress itself, and research on such a combination has not been sufficiently conducted.

Japanese Unexamined Patent Publication No. 11-158077 Japanese Unexamined Patent Publication No. 2009-126802

Therefore, the present inventors focused on γ-aminobutyric acid. It is an object of the present invention to provide an oral composition that effectively utilizes γ-aminobutyric acid.

As a result of diligent studies to solve the above problems, the present inventors have surprisingly found that the combination of γ-aminobutyric acid with chamomile has an excellent stress-reducing effect. The present invention is a completed invention based on such findings.

The outline of the present invention is as follows.
[1] (A) An oral composition for stress reduction containing γ-aminobutyric acid as an active ingredient for stress reduction, further from (B) chamomile, and (C) theanine, ceramide, elastin, hyaluronic acid and collagen. An oral composition for stress reduction, which comprises two or more selected species.
[2] An oral composition comprising (A) γ-aminobutyric acid, (B) chamomile, and (C) two or more selected from theanine, ceramide, elastin, hyaluronic acid and collagen.
[3] (A) An oral composition for stress reduction containing γ-aminobutyric acid as an active ingredient for stress reduction, further from (B) chamomile, and (C) theanine, ceramide, elastin, hyaluronic acid and collagen. An oral composition for stress reduction, which comprises one or more selected species.
[4] An oral composition comprising (A) γ-aminobutyric acid, (B) chamomile, and (C) one or more selected from theanine, ceramide, elastin, hyaluronic acid and collagen.
[5] An oral composition comprising (A) γ-aminobutyric acid and (B) chamomile.
[6] An oral composition for stress reduction containing (A) γ-aminobutyric acid as an active ingredient for stress reduction, and (B) an oral composition for stress reduction, which further contains (B) chamomile.

The composition of the present invention has an excellent stress-reducing effect.

Hereinafter, the present invention will be described in detail. The present invention is not limited to the following embodiments.

[A. γ-Aminobutyric acid]
The composition of the present invention contains γ-aminobutyric acid (GABA) as an essential component. γ-Aminobutyric acid is a type of amino acid widely distributed in the animal and plant kingdoms, and is an inhibitory neurotransmitter present in the brain and spinal cord of mammals. As the γ-aminobutyric acid, for example, synthetic products, tea, young barley leaves, germinated brown rice, those derived from plants such as barley, and those derived from fermented products by microorganisms such as lactic acid bacteria can be used. As the γ-aminobutyric acid derived from the fermented product, one obtained by fermenting a plant such as barley with a microorganism such as lactic acid bacteria may also be used. From the viewpoint of stress reducing action, it is particularly preferable to use a plant obtained by fermenting a plant such as barley with a microorganism such as lactic acid bacteria.

The content ratio of γ-aminobutyric acid contained in the composition of the present invention is not particularly limited, and the content ratio can be appropriately set in a wide range according to various conditions such as purpose, shape, and target of use. When the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), 0.1 to 90% by mass is preferable, and 1 to 80% by mass is more preferable. It is preferable, and the range of 5 to 65% by mass is particularly preferable. When the composition of the present invention is a liquid (liquid, gel, paste, etc.), it is preferably 0.00001 to 30% by mass, more preferably 0.00005 to 20% by mass, and 0.0001 to 0.0001. 10% by mass is particularly preferable.

[B. chamomile]
The composition of the present invention contains chamomile as an essential ingredient. Chamomile (Matricaria recutita L) is an annual plant of the genus Mayweed in the family Asteraceae, and is also known as chamomile, chamomile, chamomile, Zelman, German chamomile, chamomile German, chamomile, and German chamomile. As the site where the chamomile is used, the whole may be used, or a specific site such as a plant leaf, flower, root, stem, underground stem (rhizome, bulb stem, lump stem, scale stem), seed, bud, etc. may be used. Although there is no particular limitation, from the viewpoint of stress reducing action, above-ground parts (flowers, leaves, stems) are preferable, and flowers are particularly preferable. The method for treating chamomile is not particularly limited, but from the viewpoint of stress reducing action, crushed products, squeezed products and extracts are preferable, and squeezed products and extracts are particularly preferable. The extraction solvent for preparing the chamomile extract is not particularly limited, but water, a water-soluble organic solvent, and a liquid for mixing water and a water-soluble organic solvent can be used. Examples of the water-soluble organic solvent include ethanol and methanol, and a mixed solvent of a plurality of solvents may be used as the extraction solvent, but from the viewpoint of stress reduction, chamomile flowers extracted with a hydrous ethanol solution are particularly preferable. .. In addition, the chamomile extract may be mixed with an excipient such as dextrin and cyclodextrin, if necessary.

The content ratio of chamomile is not particularly limited, and the content ratio can be appropriately set in a wide range according to various conditions such as purpose, shape, and target of use. When the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), 0.005 to 15% by mass is preferable, and 0.01 to 10% by mass is preferable. Is more preferable, and a range of 0.05 to 5% by mass is particularly preferable. When the composition of the present invention is a liquid (liquid, gel, paste, etc.), it is preferably 0.00001 to 15% by mass, more preferably 0.00005 to 10% by mass, and 0.0001 to 0.0001. 5% by mass is particularly preferable.

[C. Theanine, ceramide, elastin, hyaluronic acid, collagen]
The composition of the present invention can contain one or more selected from (C) theanine, ceramide, elastin, hyaluronic acid and collagen in addition to (A) γ-aminobutyric acid and (B) chamomile.

[Theanine]
Theanine is a kind of amino acid contained in tea, and is also referred to as γ-glutamylethylamide or γ- (ethylamide) L-glutamic acid. The theanine used in the present invention is not particularly limited, but L-theanine is particularly preferable. The method for producing theanine is not particularly limited, but those obtained by extraction from plants, those obtained by chemical synthesis, and those obtained by fermentation can be used. Theanine is commercially available as a reagent, a food additive, etc., and it is particularly preferable to use a reagent.

The content ratio of theanine is not particularly limited, and the content ratio can be appropriately set in a wide range according to various conditions such as purpose, shape, and target of use. When the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), 0.005 to 30% by mass is preferable, and 0.01 to 20% by mass is preferable. Is more preferable, and a range of 0.05 to 10% by mass is particularly preferable. When the composition of the present invention is a liquid (liquid, gel, paste, etc.), it is preferably 0.00001 to 15% by mass, more preferably 0.00005 to 10% by mass, and 0.0001 to 0.0001. 5% by mass is particularly preferable.

[Ceramide]
Ceramide is an amide bond between sphingosine and fatty acid. The ceramide used in the present invention is not particularly limited, but in addition to human-type ceramides such as ceramide 1, ceramide 2, and ceramide 3, animal-derived ceramides, wheat, etc. extracted from the brain, spinal cord, etc. of cows, horses, pigs, etc. Plant-derived ceramides extracted from rice, soybeans, spinach, corn, konjac, pineapple and the like can be used. From the viewpoint of stress reducing action, rice-derived ceramide is preferable, and rice-derived ceramide, which is a rice seed, is particularly preferable. Further, the ceramide used in the present invention may be sugar ceramide, and specific examples thereof include those to which monosaccharides such as galactosylceramide and glucosylceramide are bound, and those to which oligosaccharides are bound. However, glucosylceramide is particularly preferable from the viewpoint of stress reducing action. The solvent used for extracting the ceramide used in the present invention includes, for example, water; lower alcohols such as ethanol, methanol, isopropanol and butanol; lower esters such as ethyl acetate and methyl acetate; acetone; and a mixture thereof with water. Examples include solvents. The temperature of the extraction solvent can be appropriately set from room temperature to below the boiling point depending on the solvent used. The extraction solvent in the present invention is particularly preferably ethanol or hydrous ethanol because the active ingredient can be efficiently extracted.

The content ratio of ceramide is not particularly limited, and the content ratio can be appropriately set in a wide range according to various conditions such as purpose, shape, and target of use. When the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), 0.005 to 15% by mass is preferable, and 0.01 to 10% by mass is preferable. Is more preferable, and a range of 0.05 to 5% by mass is particularly preferable. When the composition of the present invention is a liquid (liquid, gel, paste, etc.), it is preferably 0.00001 to 15% by mass, more preferably 0.00005 to 10% by mass, and 0.0001 to 0.0001. 5% by mass is particularly preferable.

[Elastin]
Elastin is a major protein that exists together with collagen and has elasticity in mammals, birds, fish, etc., especially in the aorta, nuchal ligament, yellow ligament, lung, skin, uterus, elastic cartilage, etc. of mammals, and is also known as elastic. Also called fiber. The elastin used in the present invention includes hydrolyzed elastin, α-elastin, κ-elastin, elastin peptide and the like in addition to water-soluble elastin. The elastin used in the present invention is not particularly limited, but hydrolyzed skin and connective tissue of fish such as cod, mackerel, salmon, herring, Thailand, tuna and sardine can be used. In the present invention, elastin obtained by hydrolyzing cod skin is particularly preferable from the viewpoint of stress reducing action.

The content ratio of elastin is not particularly limited, and the content ratio can be appropriately set in a wide range according to various conditions such as purpose, shape, and target of use. When the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), 0.005 to 15% by mass is preferable, and 0.01 to 10% by mass is preferable. Is more preferable, and a range of 0.05 to 5% by mass is particularly preferable. When the composition of the present invention is a liquid (liquid, gel, paste, etc.), it is preferably 0.00001 to 15% by mass, more preferably 0.00005 to 10% by mass, and 0.0001 to 0.0001. 5% by mass is particularly preferable.

[hyaluronic acid]
Hyaluronic acid is a type of mucopolysaccharide present in the skin, joints, vitreous body of the eyeball, etc. of humans and vertebrates, and is also called hyaluronan. The hyaluronic acid used in the present invention is not particularly limited, but one derived from a comb, one derived from a microorganism, a synthetic product, one hydrolyzed using an enzyme or the like can be used. Hyaluronic acid in the present invention is a concept including salts of hyaluronic acid such as sodium hyaluronate and potassium hyaluronate, and decomposition products obtained by lowering the molecular weight of hyaluronic acid such as hydrolyzed hyaluronic acid. As the hyaluronic acid of the present invention, sodium hyaluronate is particularly preferable from the viewpoint of stress reducing action. Further, the molecular weight of hyaluronic acid used in the present invention varies depending on the number and types of repeating units, and is not limited. Hyaluronic acid having a weight average molecular weight of several hundreds to several millions may be used, and hydrolyzed hyaluronic acid having an average molecular weight of 10,000 or less may be used.

The content ratio of hyaluronic acid is not particularly limited, and the content ratio can be appropriately set in a wide range according to various conditions such as purpose, shape, and target of use. When the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), 0.005 to 15% by mass is preferable, and 0.01 to 10% by mass is preferable. Is more preferable, and a range of 0.05 to 5% by mass is particularly preferable. When the composition of the present invention is a liquid (liquid, gel, paste, etc.), it is preferably 0.00001 to 15% by mass, more preferably 0.00005 to 10% by mass, and 0.0001 to 0.0001. 5% by mass is particularly preferable.

[collagen]
Collagen is a type of protein that mainly constitutes the dermis, ligaments, tendons, bones, cartilage, etc. of vertebrates, and is the main component of the extracellular matrix of multicellular animals. The collagen used in the present invention is not particularly limited, but is a terror peptide obtained by treating animal-derived collagen, synthetic collagen, collagen protein, hydrolyzed collagen (collagen peptide) obtained by hydrolyzing collagen protein, and collagen molecule with a protease. Atelocollagen from which the portion has been removed can be used. As the collagen of the present invention, hydrolyzed collagen is particularly preferable from the viewpoint of stress reducing action. The average molecular weight (weight average molecular weight) of collagen of the present invention is not particularly limited, but for example, the lower limit of the average molecular weight is preferably 100 or more, more preferably 300 or more, and particularly preferably 500 or more. The upper limit of the molecular weight is preferably 100,000 or less, more preferably 80,000 or less, and particularly preferably 50,000 or less.

The content ratio of collagen is not particularly limited, and the content ratio can be appropriately set in a wide range according to various conditions such as purpose, shape, and target of use. When the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), 0.005 to 15% by mass is preferable, and 0.01 to 10% by mass is preferable. Is more preferable, and a range of 0.05 to 5% by mass is particularly preferable. When the composition of the present invention is a liquid (liquid, gel, paste, etc.), it is preferably 0.00001 to 15% by mass, more preferably 0.00005 to 10% by mass, and 0.0001 to 0.0001. 5% by mass is particularly preferable.

In the composition of the present invention, as one or more components selected from (C) theanine, ceramide, elastin, hyaluronic acid and collagen, one or more of these may be contained from the viewpoint of stress reducing action. It is preferable to contain 2 or more kinds, more preferably 3 kinds or more, particularly preferably 4 kinds or more, and most preferably 5 kinds.

In the composition of the present invention, the content ratio of one or more selected from (C) theanine, ceramide, elastin, hyaluronic acid and collagen is not particularly limited, and may be subject to various conditions such as purpose, shape and target of use. Therefore, the content ratio can be appropriately set in a wide range. When the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), 0.005 to 60% by mass is preferable, and 0.01 to 40% by mass is preferable. Is more preferable, and a range of 0.05 to 30% by mass is particularly preferable. When the composition of the present invention is a liquid agent (liquid, gel, paste, etc.), it is preferably 0.00001 to 60% by mass, more preferably 0.00005 to 40% by mass, and 0.0001 to 0.0001. 20% by mass is particularly preferable. The content ratio of (C) in the case of containing two or more kinds selected from theanine, ceramide, elastin, hyaluronic acid and collagen means the total amount of each component.

In the composition of the present invention, the total content of one or more selected from (A) γ-aminobutyric acid, (B) chamomile, (C) theanine, ceramide, elastin, hyaluronic acid and collagen is particularly limited. However, the content ratio can be appropriately set in a wide range according to various conditions such as purpose, shape, and target of use. When the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), 0.1 to 99% by mass is preferable, and 1 to 85% by mass is more preferable. It is preferable, and 10 to 80% by mass is particularly preferable. When the composition of the present invention is a liquid (liquid, gel, paste, etc.), it is preferably 0.00001 to 70% by mass, more preferably 0.00005 to 60% by mass, and 0.0001 to 0.0001. 50% by mass is particularly preferable. The content ratio of (C) in the case of containing two or more kinds selected from theanine, ceramide, elastin, hyaluronic acid and collagen means the total amount of each component.

In the present invention, the mass ratio of (A) to the total mass of one or more selected from (A) γ-aminobutyric acid, (B) chamomile, (C) theanine, ceramide, elastin, hyaluronic acid and collagen is particularly limited. However, from the viewpoint of stress reducing action, (A) is preferably 0.0001 to 0.9 times, more preferably 0.0005 to 0.8 times, and 0 times the total mass of (A) to (C). .001 to 0.5 times is particularly preferable. The mass of (C) in the case of containing two or more kinds selected from theanine, ceramide, elastin, hyaluronic acid and collagen means the total amount of each component.

In the present invention, the mass ratio of (B) to the total mass of one or more selected from (A) γ-aminobutyric acid, (B) chamomile, (C) theanine, ceramide, elastin, hyaluronic acid and collagen is particularly limited. However, from the viewpoint of stress reducing action, (B) is preferably 0.0001 to 0.9 times, more preferably 0.0005 to 0.8 times, and 0 times the total mass of (A) to (C). .001 to 0.5 times is particularly preferable. The mass of (C) in the case of containing two or more kinds selected from theanine, ceramide, elastin, hyaluronic acid and collagen means the total amount of each component.

In the present invention, the mass ratio of (C) to the total mass of one or more selected from (A) γ-aminobutyric acid, (B) chamomile, (C) theanine, ceramide, elastin, hyaluronic acid and collagen is particularly limited. However, from the viewpoint of stress reducing action, (C) is preferably 0.0001 to 0.9 times, more preferably 0.0005 to 0.8 times, and 0 times the total mass of (A) to (C). .001 to 0.5 times is particularly preferable. The mass of (C) in the case of containing two or more kinds selected from theanine, ceramide, elastin, hyaluronic acid and collagen means the total amount of each component.

In the composition of the present invention, the ratio of the total mass of one or more selected from (C) theanine, ceramide, elastin, hyaluronic acid and collagen to the total mass of (A) γ-aminobutyric acid and (B) chamomile. Is not particularly limited, but from the viewpoint of stress reducing action, (C) is preferably 0.00001 to 10 times, more preferably 0.00005 to 5 times, and 0, with respect to the total mass of (A) and (B). .0001 to 1 times is particularly preferable. The mass of (C) in the case of containing two or more kinds selected from theanine, ceramide, elastin, hyaluronic acid and collagen means the total amount of each component.

In the composition of the present invention, the ratio of the mass of (B) chamomile to the mass of (A) γ-aminobutyric acid is not particularly limited, but from the viewpoint of stress reducing action, (B) is 0. It is preferably 0.0001 to 10 times, more preferably 0.000005 to 5 times, and particularly preferably 0.00001 to 1 time.

In the composition of the present invention, the ratio of the total mass of one or more selected from (A) theanine, ceramide, elastin, hyaluronic acid and collagen to the mass of (A) γ-aminobutyric acid is not particularly limited, but stress reduction. From the viewpoint of action, (C) is preferably 0.00001 to 10 times, more preferably 0.00005 to 5 times, and particularly preferably 0.0001 to 1 times with respect to (A). The mass of (C) in the case of containing two or more kinds selected from theanine, ceramide, elastin, hyaluronic acid and collagen means the total amount of each component.

In the composition of the present invention, the ratio of the total mass of one or more selected from (B) theanine, ceramide, elastin, hyaluronic acid and collagen to the mass of (B) chamomile is not particularly limited, but from the viewpoint of stress reducing action. Therefore, (C) is preferably 0.01 to 1000 times, more preferably 0.05 to 500 times, and particularly preferably 0.1 to 200 times with respect to (B). The mass of (C) in the case of containing two or more kinds selected from theanine, ceramide, elastin, hyaluronic acid and collagen means the total amount of each component.

The daily amount of the composition of the present invention to be used is not particularly limited, and when the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), the composition is not particularly limited. Based on the weight of the user, 0.1 to 1000 mg / kg is preferable, 0.5 to 500 mg / kg is more preferable, and 1 to 100 mg / kg is particularly preferable from the viewpoint of stress reducing action. When the composition of the present invention is a liquid (liquid, gel, paste, etc.), 100 to 40,000 mg / kg is preferable, and 300 to 30,000 mg / kg is more preferable, based on the body weight of the user. From the viewpoint of stress reducing action, 500 to 20000 mg / kg is particularly preferable.

The amount of the composition of the present invention used at one time is not particularly limited, and when the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), Based on the weight of the user, 0.1 to 1000 mg / kg is preferable, 0.5 to 500 mg / kg is more preferable, and 1 to 100 mg / kg is particularly preferable from the viewpoint of stress reducing action. When the composition of the present invention is a liquid (liquid, gel, paste, etc.), 100 to 40,000 mg / kg is preferable, and 300 to 30,000 mg / kg is more preferable, based on the body weight of the user. From the viewpoint of stress reducing action, 500 to 20000 mg / kg is particularly preferable.

The daily amount of the composition of the present invention to be used is not particularly limited, and when the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), the composition is not particularly limited. 0.01 to 10 g is preferable, 0.1 to 5 g is more preferable, and 0.2 to 3 g is particularly preferable from the viewpoint of stress reducing action. When the composition of the present invention is a liquid (liquid, gel, paste, etc.), 10 to 1000 g is preferable, 30 to 750 g is more preferable, and 50 to 500 g is particularly preferable from the viewpoint of stress reducing action. preferable.

The amount of the composition of the present invention used at one time is not particularly limited, and when the composition of the present invention is a solid agent (powder, granule, granule, tablet, capsule, chewable, etc.), 0.01 to 10 g is preferable, 0.1 to 5 g is more preferable, and 0.2 to 3 g is particularly preferable from the viewpoint of stress reducing action. When the composition of the present invention is a liquid (liquid, gel, paste, etc.), 10 to 1000 g is preferable, 30 to 750 g is more preferable, and 50 to 500 g is particularly preferable from the viewpoint of stress reducing action. preferable.

The composition of the present invention may contain only one or more selected from (A) γ-aminobutyric acid, (B) chamomile, (C) theanine, ceramide, elastin, hyaluronic acid and collagen. However, other components may be contained in addition to the above components. Other ingredients include, for example, various excipients, binders, lubricants, stabilizers, diluents, bulking agents, thickeners, emulsifiers, colorants, fragrances, additives, cosmetic raw materials, pharmaceutical raw materials, etc. Can be mentioned. The content of other components can be appropriately selected depending on the usage mode of the composition of the present invention and the like.

The composition of the present invention can be used in various forms for the purpose of obtaining a stress-reducing effect.

The composition of the present invention is not particularly limited as long as it can be distinguished from other products as a product in that it is used for a stress reducing action. For example, the main body and packaging of the product according to the present invention. , The instruction manual, or the advertisement indicating that the product has a stress-reducing effect is included in the scope of the present invention. For example, so-called health foods such as pharmaceuticals (including non-pharmaceutical products), foods for specified health use, foods with nutritional function, foods with functional claims, etc. Can be mentioned. In so-called health foods, "relieve stress", "relieve temporary stress", "relieve temporary mental stress caused by work or study", "temporary stress caused by work" (feeling frustrated) ) Is alleviated ”,“ useful for alleviating transient stress ”, etc. can be exemplified.

The form of the composition of the present invention is not particularly limited and may be any form. For example, suitable forms for oral compositions, specifically powdery, granular, granular, tablet, liquid, gel, paste, capsules such as hard capsules and soft capsules, caplets, chewables, etc. Each form is listed, and various excipients, binders, lubricants, stabilizers, diluents, bulking agents, thickeners, gelling agents, emulsifiers, colorants, fragrances, etc. It can contain sweeteners, additives and the like. From the viewpoint of stress reducing action, the composition of the present invention is preferably in the form of granules, tablets, liquids, gels, capsules and chewables, and more preferably in the form of granules, tablets and capsules. Here, the granular form refers to a composition obtained by granulating powder, and the gel form refers to a composition containing water and a gelling agent and having viscosity or elasticity.

The packaging form of the composition of the present invention is not particularly limited and may be appropriately selected depending on the dosage form and the like. For example, a blister pack such as PTP; strip packaging; heat seal; aluminum pouch; a film using plastic or synthetic resin. Packaging; glass containers such as vials; plastic containers such as ampoules.

Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples, and the present invention can take various aspects as long as the problems of the present invention can be solved. ..

(Test substance)
Test substances include γ-aminobutyric acid (fermented barley with lactic acid bacteria), chamomile extract (chamomile flowers extracted with 50% hydrous ethanol solution), and rice-derived glucosylceramide (rice extracted with ethanol). , Elastin (hydrolyzed cod skin), sodium hyaluronate (average molecular weight 1.2 million), and hydrolyzed collagen (average molecular weight 2000) were used (all are commercially available products). Moreover, as the theanine, a reagent (synthetic product of L-theanine) was used.

(Test method)
Rat adrenal pheochromocytoma cells (PC12, JCRB cell bank) were cultured in 10 volume% FBS-RPMI 1640 medium and 100 μL / well seeded on a collagen-coated 96-well plate at 4 × 10 ^ 4 cells / well. , 37 ° C., pre-cultured in 5 volume% CO2 incubator for 24 hours.

After culturing for 24 hours, 100 μL / well of the test substance-containing medium was added from the medium already in the well, and the cells were cultured at 37 ° C. in a 5 volume% CO2 incubator for 24 hours. As the medium, 10 volume% FBS-RPMI 1640 medium was used. The concentration (μg / mL) of each component in the test substance is shown in Tables 1 and 2. The concentration of the total amount of the test substance in Examples 1 to 10 and Comparative Examples 1 to 9 in the medium is 2.5 μg / mL.

After culturing for 24 hours, hydrogen peroxide was diluted to 2.2 mM in 10 volume% FBS-RPMI 1640 medium and 20 μL / well was added over the medium already in the well (final concentration 200 μM). The cells were cultured at 37 ° C. in a 5 volume% CO2 incubator for 2 hours.

After removing the medium from each well, RNA was recovered using CellAmp Direct RNA Prep Kit for RT-PCR (manufactured by Takara). From the obtained RNA, quantitative real-time PCR was performed using One Step TB Green® PrimeScript RT-PCR Kit II (manufactured by Takara). The gene expression level of the HO-1 gene was measured using a primer of the HO-1 gene (Hmax1) (manufactured by QIAGEN, trade name: Rn_Hmax1_1_SG QuantiTectPrimerAssay (QT00175994)). As an endogenous control, the gene expression level of GAPDH was measured using a primer of GAPDH (manufactured by QIAGEN, trade name: Rn_Gapt_1_SG QuantiTect Primer Assay (QT00199633)). The relative value of the HO-1 gene expression level was calculated when the expression level of the group (control) to which the test substance was not administered was 1.

The results are shown in Tables 1 and 2.

It is considered that one of the causes of feeling psychological stress is that various stresses cause oxidative stress and mitochondrial damage and induce nerve cell damage. Heme Oxygenase 1 (hereinafter, also referred to as “HO-1”) is known to have a mitochondrial protective effect under oxidative stress. From this, it is considered that the composition that enhances the gene expression of HO-1 is useful for improving the resistance to various stresses.

No increase in the amount of HO-1 gene was confirmed in each component of Comparative Examples 1 and 2, but surprisingly, in Example 1 in which (A) γ-aminobutyric acid and (B) chamomile were combined. , An increase in the expression level of HO-1 was confirmed. Further, when (A) γ-aminobutyric acid was combined with (C) theanine or rice-derived glucosylceramide as in Comparative Examples 8 and 9, no increase in the amount of HO-1 gene was confirmed. It was found that the combination of A) γ-aminobutyric acid and (B) chamomile was particularly effective in increasing the HO-1 gene, and the composition of such a combination was effective in reducing stress. It turned out.

As can be seen from Comparative Examples 1 to 3 and 8, HO in (A) γ-aminobutyric acid, (B) chamomile and (C) theanine alone, or in combination of (A) γ-aminobutyric acid and (C) theanine. No increase in the amount of -1 gene was confirmed, but Example 2 in which these three components were combined showed an excellent increase in the amount of HO-1 gene. In particular, it is surprising that the amount of the HO-1 gene was increased as compared with Example 1. Further, as can be seen from Comparative Examples 1, 2, 4, and 9, (A) γ-aminobutyric acid, (B) chamomile and (C) rice-derived glucosylceramide alone, or (A) γ-aminobutyric acid and (C) ) No increase in the amount of HO-1 gene was confirmed in the combination of rice-derived glucosylceramide, but Example 3 in which these three components were combined showed an excellent increase in the amount of HO-1 gene. In particular, it is surprising that the amount of the HO-1 gene was increased as compared with Example 1. Furthermore, as can be seen from Comparative Examples 1, 2 and 5, no increase in the amount of HO-1 gene was confirmed in each of (A) γ-aminobutyric acid, (B) chamomile and (C) elastin alone, but these 3 Example 4 in which the components were combined showed an excellent increase in the amount of HO-1 gene. In particular, it is surprising that the amount of the HO-1 gene was increased as compared with Example 1.

As can be seen from Comparative Examples 1 to 4, 8 and 9, (A) γ-aminobutyric acid, (B) chamomile and (C) theanine, rice-derived glucosylceramide alone, or (A) γ-aminobutyric acid and (A) γ-aminobutyric acid and ( No increase in the amount of HO-1 gene was confirmed in the combination of C) theanine or (A) γ-aminobutyric acid and (C) rice-derived glucosylceramide, but Example 5 in which these four components were combined was excellent. It showed an increase in the amount of HO-1 gene. In particular, it is surprising that the amount of the HO-1 gene was increased as compared with Examples 1 to 4. Further, as can be seen from Comparative Examples 1, 2, 4, 5, and 9, (A) γ-aminobutyric acid, (B) chamomile and (C) rice-derived glucosylceramide, and elastin are each alone, or (A) γ-. No increase in the amount of HO-1 gene was confirmed in the combination of aminobutyric acid and (C) rice-derived glucosylceramide, but Example 6 in which these four components were combined showed an excellent increase in the amount of HO-1 gene. .. In particular, it is surprising that the amount of the HO-1 gene was increased as compared with Examples 1 to 4.

As can be seen from Comparative Examples 1 to 5, 8 and 9, (A) γ-aminobutyric acid, (B) chamomile and (C) theanine, rice-derived glucosylceramide and elastin are used alone, or (A) γ-aminobutyric acid. No increase in the amount of HO-1 gene was confirmed in the combination of (C) theanine or (A) γ-aminobutyric acid and (C) rice-derived glucosylceramide. Showed an excellent increase in the amount of HO-1 gene. In particular, it is surprising that the amount of the HO-1 gene was increased as compared with Examples 1 to 6. Further, as can be seen from Comparative Examples 1, 2, 4 to 6 and 9, (A) γ-aminobutyric acid, (B) chamomile and (C) rice-derived glucosylceramide, elastin, sodium hyaluronate, respectively, or ( A) No increase in the amount of HO-1 gene was confirmed in the combination of γ-aminobutyric acid and (C) rice-derived glucosylceramide, but Example 8 in which these five components were combined had an excellent amount of HO-1 gene. Showed an increase. In particular, it is surprising that the amount of the HO-1 gene was increased as compared with Examples 1 to 6.

As can be seen from Comparative Examples 1, 2, 4 to 7, 9, (A) γ-aminobutyric acid, (B) chamomile and (C) rice-derived glucosylceramide, elastin, sodium hyaluronate, hydrolyzed sodium, respectively, or , (A) γ-aminobutyric acid and (C) rice-derived glucosylceramide did not confirm an increase in the amount of the HO-1 gene, but Example 9 in which these 6 components were combined showed an excellent HO-1 gene. Showed an increase in volume. In particular, it is surprising that the amount of the HO-1 gene was increased as compared with Examples 1 to 8.

As can be seen from Comparative Examples 1 to 9, (A) γ-aminobutyric acid, (B) chamomile and (C) theanine, rice-derived glucosylceramide, elastin, sodium hyaluronate, and hydrolyzed sodium are used alone or (A). No increase in the amount of HO-1 gene was confirmed in the combination of γ-aminobutyric acid and (C) theanine, or (A) γ-aminobutyric acid and (C) rice-derived glucosylceramide, but these 7 components were combined. Example 10 showed an excellent increase in the amount of HO-1 gene. In particular, it is surprising that the amount of the HO-1 gene was increased as compared with Examples 1 to 9.

Based on the above, the composition containing (A) γ-aminobutyric acid and (B) chamomile of the present invention has a stress-reducing effect, and (C) theanine, rice-derived glucosylceramide, elastin, sodium hyaluronate, and water are added. An excellent stress-reducing effect can be achieved by further combining one or more, preferably two or more, more preferably three or more, particularly preferably four or more, and most preferably five, selected from the decomposed collagen. It turned out.

(Manufacturing example)
A production example of the present invention is shown below. In addition,% in Tables 3-9 represents mass%.

[Production Example 1-4: Granules]
After mixing the raw materials as shown in Table 3, fluidized bed granulation was performed using a granulator to produce the granules described in Production Examples 1-4. The granules described in Production Examples 1-4 may be ingested in an amount of 3 g per day, may be ingested by dissolving in a solvent such as 100 ml of water, or may be ingested as it is without being dissolved. Any of the granules of Production Examples 1-4 are effective in reducing stress.

[Production Example 5-8: Tablets]
After mixing the raw materials as shown in Table 4, tableting was performed using a rotary tableting machine to produce tablets of Production Example 5-8. The tablets were produced with a tablet diameter of 8 mmφ, a tablet thickness of 4.5 mm, a weight of 300 mg, and a hardness of 5 kgf or more. The tablets described in Production Example 5-8 may be ingested 1 to 2 tablets per day, and can be ingested together with 100 ml of water or the like. Any of the tablets of Production Example 5-8 is effective in reducing stress.

[Manufacturing Example 9-34: Hard Capsule]
As shown in Table 5-9, the raw materials were mixed and encapsulated with a film containing gelatin or hydroxypropyl cellulose to produce a hard capsule. The hard capsule was manufactured with 300 mg per capsule (content 230 mg, film 70 mg). It is sufficient to take 1 to 2 tablets per day, and it can be taken with 100 ml of water or the like. Further, any of the hard capsules of Production Examples 9-34 is effective in reducing stress.

Since the composition of the present invention has an excellent stress-reducing effect, it is highly industrially useful.

Claims (2)

(A) An oral composition for stress reduction for relieving temporary mental stress, wherein γ-aminobutyric acid is used as an active ingredient for stress reduction for relieving temporary mental stress , and further (B). ) Chamomile, and (C) two or more selected from theanine, ceramide, elastin, hyaluronic acid and collagen, and at least one of (C) is characterized by being elastin or hyaluronic acid. An oral composition for stress relief to relieve temporary psychological stress . (A) An oral composition for stress reduction for relieving temporary mental stress, wherein γ-aminobutyric acid is used as an active ingredient for stress reduction for relieving temporary mental stress , and further (B). ) A stress-relieving oral composition for relieving temporary psychological stress, which comprises chamomile and (C) at least one selected from elastin and hyaluronic acid.